Goldline Pharmaceutical IPO

Goldline Pharmaceutical IPO Details

Goldline Pharmaceutical IPO is a 100% book-built issue of ₹11.61 crore, entirely a fresh issue of 0.27 crore equity shares, with a face value of ₹10 per share. The company filed its DRHP with SBEI on September 30, 2025.

The price band is set at ₹41 to ₹43 per share and the lot size for an application is 3,000 shares. The minimum amount of investment required by an individual investor (retail investor) is ₹2,58,000. The IPO will open for subscription from May 12 to 14, 2026, on the BSE SME platform, with a tentative listing date fixed as May 19, 2026. The book-running lead manager to the issue is Cumulative Capital Private Ltd., while the registrar to the issue is Bigshare Services Private Ltd.

Goldline Pharmaceutical IPO Date & Timeline

The Goldline Pharmaceutical IPO is officially set to open for subscription on May 12, 2026 and will close on May 14, 2026. The company initially filed its Draft Red Herring Prospectus (DRHP) on September 30, 2025 and has now finalised its schedule following SEBI approval. Once the subscription window allotment is expected on May 15, 2026. Following this, the company will initiate refunds and credit shares to successful investors' demat accounts on May 18, 2026. Finally, Goldline Pharmaceutical Ltd.'s shares are tentatively scheduled to list on the stock exchanges on May 19, 2026.

Goldline Pharmaceutical IPO GMP (Grey Market Premium)

“Grey Market Premium” or GMP is defined as the rate at which the IPO's shares are traded in the market before they are officially listed on the stock exchange.

The Goldline Pharmaceutical IPO GMP is currently trading at ₹[.], reflecting the sentiment of unofficial investors before the official listing. This premium suggests a potential listing price of ₹[.], which is [.]% above the issue price. While the Grey Market Premium is a key indicator of demand and investor appetite, it is important to remember that GMP is highly volatile and should not be the sole factor in your investment decisions.

Company Background

Goldline Pharmaceutical Ltd. was incorporated on August 2, 2004, as a private limited company under the name 'Goldline Pharmaceutical Private Limited' in Mumbai. Over the years, the company transitioned its corporate structure, becoming a public limited company in July 2013 and subsequently moving its registered office to Nagpur, Maharashtra.

The company has focused on the pharmaceutical sector, evolving its operations to specialise in the marketing and distribution of medicinal products rather than direct manufacturing. Goldline doesn't work as a manufacturer here; they do contractual agreements with 3rd-party manufacturers, who perform the manufacturing process on the basis of Goldline’s research and market analysis.

Operations & Product Range

The corporate structure of Goldline Pharmaceutical Ltd. engages in marketing and material sourcing activities. This firm manufactures a broad spectrum of products from different therapeutic lines such as antibiotics, analgesics and dietary supplements. Some of its prominent registered trademarks include AMCLUE, AZITHREE, CABGOLD and CHYMOGOLD. It serves as an intermediary in this process, whereby it collaborates with manufacturers in ensuring that all the products are up to par in terms of quality.

Facilities & Capacity

The Goldline Pharmaceutical Ltd. follows a lean business model that makes use of minimal assets for operations. The firm does not manufacture any of its branded products since it is dependent upon third-party contractors who manufacture its pharmaceuticals according to the company’s market analysis. Its efforts have been focused on marketing its brand name and managing its logistics and supply chain management activities. Its operations are run from Nagpur, where its headquarters and registered office are situated.

Brands & Market Presence

Goldline Pharmaceutical Ltd. has established a recognizable presence in the domestic market through its suite of registered pharmaceutical brands. By focusing on therapeutic areas with consistent demand, Goldline has built a distribution network that caters to various healthcare providers. Its market presence is primarily domestic and it operates under its brand "Goldline Pharmaceutical Limited"; also, its associated logo is central to its market identity, with several key product names having secured long-term trademark registrations.

Revenue Streams & Business Model

The primary revenue source for Goldline Pharmaceutical Ltd. is the sale of pharmaceutical products. For FY25, the revenue from operations was ₹28.05 crore and the net profit for the year was at ₹2.83 crore. The business model is centred on identifying market needs, coordinating production with contract partners and leveraging an established distribution network to fulfil orders from wholesalers and doctors.

Management & Shareholding

Goldline Pharmaceutical Ltd. is led by its promoters, Amol Laxmikant Mujumdar and Swapan Premprakash Khandelwal. Before the IPO, the promoters held the 79.70% stake, but after the IPO, the promoters' shareholding will be diluted, not by stakeholding, as there is no OFS in the offering.

Board & Key Management

The leadership of Goldline Pharmaceutical Ltd. is led by a team of experts with many years of experience. Amol Laxmikant Mujumdar serves as the Chairman & Managing Director and gives strategic direction to the firm and the daily operations, along with Whole-Time Director Swapan Premprakash Khandelwal. To ensure good governance, the board includes independent directors Mehul Hari Ranade and Renuka Saurabh Borole for honest oversight. Together, this team uses its knowledge to help the company grow and stay successful.